Best Life Sciences Companies in Ness Ziona, Israel
The 60 best Life Sciences companies in Ness Ziona, Israel in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Emendo Biotherapeutics.
Our analysis of 50 Life Sciences companies
$2.2b in tracked funding; 75% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2024.
Ranked: Best Life Sciences companies in Ness Ziona
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Emendo Biotherapeutics Provider of re-designed gene-editing tools as drugs for genetic disorders | $61M | 77 mo ago | 116 | 2015 | Shilo Ben Zeev Co-Founder | WordPressMySQLPHP+23 | — | — |
| 2 | BiomX Microbiome therapeutics for diseases associated with microbiome dysbiosis 62Funding top 20%Patents top 34%Growth top 37%Tech top 37% All 9 signals ▾Fundingtop 20% Patentstop 34% Growthtop 37% Techtop 37% Moattop 38% Innovationtop 45% Marketbottom 47% Newsbottom 44% Globalbottom 44% Funding: Raised $56.0M across 7 rounds · 7 rounds over 9 yrs (0.8/yr) Patents: 42 patents matched (strict assignee match) · 24 filings since 2022 vs 18 in 2017-21 rank vs industry peers · Fliar Intelligence Index 62/100 | $56M | 5 mo ago | 65 | 2015 | — | DrupalPHPAmazon Web Services+26 | 42 patents Therapeutic bacteriophage engineering for targeted bacterial infection and gut microbiome modulation | 2 launchs |
| 3 | BiondVax Developer of a vaccine against influenza virus | $50M | 86 mo ago | — | 2003 | Amir Reichman Chief Executive Officer | — | — | — |
| 4 | Innoventric Developer of transcatheter solutions for patients with heart diseases 40Funding top 31%Moat top 32%Innovation top 41%Patents top 42% All 7 signals ▾Fundingtop 31% Moattop 32% Innovationtop 41% Patentstop 42% Talentbottom 49% Globalbottom 43% Marketbottom 35% Funding: Raised $41.8M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) Moat: Editorial + unicorn rating 4/10 · IP moat: 37 patents rank vs industry peers · Fliar Intelligence Index 40/100 | $42M | 20 mo ago | 17 | 2017 | Rafi Benary Founder | — | 37 patents Percutaneous tricuspid valve repair and implantation devices and storage solutions | — |
| 5 | Mapi Pharma Clinical stage pharmaceutical company developing extended release versions of generic drugs. | $40M | 72 mo ago | 38 | 2008 | Ehud Marom Chairman & Ceo | WordPressMySQLPHP+15 | 325 patents Patents concentrated in health & consumer products | — |
| 6 | EyeYon Developer of ophthalmic devices for the treatment of corneal edema | $36M | 63 mo ago | 19 | 2011 | Nahum Ferera Co-Founder & CEO | WordPressMySQLPHP+19 | — | 1 expansion |
| 7 | Regenera Pharma Israeli, clinical stage biopharma developing botanically-derived small molecule therapeutics for optic nerve… | $23M | 102 mo ago | 6 | 2008 | Konstantin Adamsky CEO | — | 143 patents Patents concentrated in health & consumer products | — |
| 8 | Kadimastem Stem Cell for the treatment of diabetes mellitus and amyotrophic lateral sclerosis (ALS) | $18M | 56 mo ago | 31 | 2009 | — | WixSentryBootstrap+12 | 54 patents Generation and purification of pancreatic endocrine cells for therapeutic applications | 1 partnership |
| 9 | Core Dynamics Organ preservation technologies for the freezing, thawing, and freeze-drying of cells. | $18M | 206 mo ago | — | 2005 | Sachi Norman CEO | — | 11 patents Cryogenic preservation and controlled cooling of biological tissues and organs | — |
| 10 | Collplant Developer of recombinant human collagen for regenerative medicine and aesthetics 53Patents top 22%Funding top 26%Product top 26%Tech top 35% All 10 signals ▾Patentstop 22% Fundingtop 26% Producttop 26% Techtop 35% Moattop 35% Innovationtop 43% Newstop 47% Growthbottom 47% Marketbottom 46% Globalbottom 43% Patents: 170 patents matched (strict assignee match) · 41 filings since 2022 vs 46 in 2017-21 Funding: Raised $16.3M across 11 rounds · 11 rounds over 20 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 53/100 | $16M | 5 mo ago | 73 | 2004 | — | WordPressMySQLPHP+21 | 170 patents Collagen-based soft tissue fillers and degradable implants for medical additive manufacturing. | — |
| 11 | NanoPass Technologies Microneedles-based device for intradermal delivery 37Innovation top 39%Patents top 39%Funding top 42%Moat top 45% All 8 signals ▾Innovationtop 39% Patentstop 39% Fundingtop 42% Moattop 45% Techtop 48% Talentbottom 49% Globalbottom 43% Marketbottom 30% Innovation: 75 patents (top 36% of patent-holders) Patents: 75 patents matched (strict assignee match) · Latest publication 2016 rank vs industry peers · Fliar Intelligence Index 37/100 | $15M | 23 mo ago | 16 | 2000 | Daniel Levitats Chief Executive Officer | WordPressMySQLPHP+25 | 75 patents Microneedle-enabled intradermal drug delivery systems and associated manufacturing technologies | 3 launchs · 1 partnership |
| 12 | Kamari Pharma Developer of therapies for rare dermatologic diseases and itch conditions 22Moat top 32%Patents top 36%Innovation top 42%Funding top 46% All 6 signals ▾Moattop 32% Patentstop 36% Innovationtop 42% Fundingtop 46% Globalbottom 40% Marketbottom 23% Moat: Editorial + unicorn rating 4/10 · IP moat: 28 patents Patents: 28 patents matched (strict assignee match) · 26 filings since 2022 vs 2 in 2017-21 rank vs industry peers · Fliar Intelligence Index 22/100 | $8M | 13 mo ago | 7 | 2018 | — | — | 28 patents Topical small‑molecule therapeutics for dermatological disorders and skin symptom relief | — |
| 13 | Quiet Therapeutics Lipid nanoparticles as a mode of delivery to target cancer cells | $6M | 161 mo ago | 4 | 2010 | Dan Peer Co-Founder | — | 8 patents Lipidated glycosaminoglycan carriers for nucleic acid delivery | — |
| 14 | NeuroDerm Therapies for Parkinson’s disease (PD) and other CNS disorders | $2M | 157 mo ago | 55 | 2003 | Ayelet Altman CEO | Apple iCloud MailPlyrUIKit+13 | 450 patents Formulations and delivery methods for Parkinson’s disease therapeutics. | — |
| 15 | miCure Therapeutics Developer of microRNA therapeutics and diagnostics for CNS disorders | $2M | 144 mo ago | — | 2013 | Michel Horovitz CEO | — | 8 patents Targeted microRNA therapeutics and neuron-specific oligonucleotide delivery platforms | — |
| 16 | Omrix Biopharmaceuticals Developer of biopharmaceutical products derived from human plasma | $2M | 257 mo ago | — | 1995 | — | — | 652 patents Oxidized cellulose-based hemostatic and anti‑adhesion biomaterials for surgical wound care | — |
| 17 | Thrombotech Peptide drug for the treatment of ischemic stroke | $1M | 172 mo ago | — | 2000 | Ruth Yakar CEO | — | 22 patents Therapeutic peptides modulating plasminogen activators for cardiovascular and hypertension treatment | — |
| 18 | Pylon Medical Manufacturer of medical devices specializing in carotid stenting | $1M | 23 mo ago | — | 2023 | Or Zigelboim Founder & CEO | — | — | — |
| 19 | Amorphical Amorphous calcium carbonate for osteoporosis & other calcium-related diseases | $1M | 147 mo ago | 15 | 2004 | Yossi Ben Founder & CEO | WordPressMySQLPHP+19 | 218 patents Pharmaceutical and nutraceutical formulations of amorphous calcium carbonate for therapeutic uses | 2 job openings |
| 20 | Phenome Networks Developer of software for plant breeding and variety testing processes | $510K | 69 mo ago | 25 | 2008 | — | WordPressMySQLPHP+31 | — | — |
| 21 | MataGene Biotechnology company offering technology to enhance crop photosynthesis using genetic engineering | $250K | 47 mo ago | — | 2021 | Vivekanand Tiwari Co-Founder | — | — | — |
Top 12 Life Sciences companies in Ness Ziona
#1
Public · Ness Ziona, Center District · founded 2015 · 65 employees$56Mraised▾
Microbiome therapeutics for diseases associated with microbiome dysbiosis. The company offers its flagship 3-tier microbiome modulation platform which is an end-to-end platform to identify target bacteria causing microbiome dysbiosis, modulate the microbiome through adding or eradicating bacteria. It also has a GI tract cancer program in prototype discovery and a checkpoint inhibitor program in target discovery.
- Jan 2026Post IPO$3.3M
- Feb 2025Post IPO$12M
- Mar 2024Post IPO$50M
- Mar 2023Post IPO$1.5M
#2
Public · Ness Ziona, Center District · founded 2004 · 73 employees$16.3Mraised▾
Developer of recombinant human collagen for regenerative medicine and aesthetics. It focuses on creating technologies and products for tissue regeneration and organ manufacturing. The company's plant-based technology enables the production of recombinant human type I collagen. This collagen is identical to that produced by the human body. The company develops products aimed at bioprinting tissues and organs and medical aesthetics.
- Feb 2026Post IPO$4M
- Feb 2020Post IPO$4.5M
- Sep 2019Post IPO$5.5M
- Nov 2017Post IPO$2M
#3
Series B · Ness Ziona, Center District · founded 2017 · 17 employees$41.8Mraised▾
Developer of transcatheter solutions for patients with heart diseases. The company's percutaneous device Trillium is designed to provide treatment of tricuspid regurgitation.
- Oct 2024Series B$28.5M
- Jun 2022Grant (prize money)$2.7M
- Nov 2021Grant (prize money)$2.9M
- Nov 2021Series A$13.3M
#4
Series A · Ness Ziona, Center District · founded 2018 · 7 employees$8Mraised▾
Developer of therapies for rare dermatologic diseases and itch conditions. It offers topical and oral TRPV3 inhibitors treatment of Lichen simplex chronicus related itch, Palmoplantar Keratoderma, and Ichthyosis.
- Jun 2025Series A$23M
- Sep 2022Series A$8M
#5
Series C · Ness Ziona, Center District · founded 2000 · 16 employees$14.9Mraised▾
NanoPass Technologies develops intradermal delivery solutions for vaccines and immunotherapies. They have developed, MicronJet needle, a single use microneedles-based device for intradermal delivery. It can be used with any standard syringe to painlessly deliver any liquid substance directly into the skin. The MicronJet can be used with any standard syringe to inject drugs, proteins and vaccines approved for that delivery route.
- Jul 2024Series C$6M
- Apr 2016Series C—
- Jul 2012Series B—
- Feb 2007Series A$6.5M
#6
Seed · Ness Ziona, Center District · founded 2023$1.2Mraised▾
Manufacturer of medical devices specializing in carotid stenting. The company's product is a percutaneous transcarotid stenting system to provide a safer method for carotid artery access, which aims to reduce complications associated with traditional approaches.
- Jul 2024Seed$1.2M
#7
Series C · Ness Ziona, Center District · founded 2011 · 19 employees$36Mraised▾
Developer of ophthalmic devices for the treatment of corneal edema. The Hyper-CL™ therapeutic contact lens for the treatment of corneal pathologies. Another product EndoArt is a polymer film implant that is attached to the posterior corneal surface to treat corneal edema secondary to endothelial dysfunction.
- Mar 2021Series C$25M
- Mar 2017Series A$6.5M
- Apr 2015Series A$3.6M
- Seed$700K
#8
Series B · Ness Ziona, Center District · founded 2008 · 38 employees$40Mraised▾
Mapi Pharma develops extended release versions of generic drugs. It uses depot delivery systems that contain multiple doses of the drug that are released over a specified period of time at desired intervals. Its lead product is a once-a-month version of glatiramer acetate for the treatment of multiple sclerosis, which is about to enter pivotal phase III trials for the 505(b)(2) regulatory pathway. In addition, the company is also developing reformulated versions of pregabalin for neuropathic pain and epilepsy, and risperidone for the treatment of schizophrenia and bipolar disorder.
- Jun 2020Series B$20M
- Nov 2018Series B$10M
- Aug 2017Series B$10M
- 2016Series A$10M
#9
Acquired · Ness Ziona, Center District · founded 2015 · 116 employees$61Mraised▾
Provider of re-designed gene-editing tools as drugs for genetic disorders. It is using protein engineering technology to re-design genome editing tools, such as CRISPR-associated protein 9 (Cas9), Transcription activator-like effector nuclease (TALEN), and Zinc fingers (ZFNs). It claims to have improved the efficacy of its drug by enhancing homology direct repair (HDR), reducing non-homologous end joining (NHEJ), increasing specificity and reducing the off-target effect.
- Jan 2020Series B$61M
#10
Public · Ness Ziona, Center District · founded 2003$49.9Mraised▾
Developer of a vaccine against influenza virus. Its lead candidate M-001, a nanosized antibody vaccine to protect against seasonal and pandemic influenza. Its technology utilizes a unique, proprietary combination of conserved and common peptides from influenza virus proteins to activate both arms of the immune system for a cross-protecting and long-lasting effect.
- Apr 2019Conventional Debt$26.9M
- Oct 2018Conventional Debt$9.2M
- Aug 2018Conventional Debt$6.8M
- Jun 2018Conventional Debt$7M
#11
Public · Ness Ziona, Center District · founded 2009 · 31 employees$18.2Mraised▾
Kadimastem is a regenerative medicine company focused on the industrial development and commercialization of stem cell-based therapeutics, primarily for diabetes and neurodegenerative disorders. The company’s proprietary technologies and know-how enable the differentiation of stem cells into insulin-secreting as a range of neural cells (Oligodendrocytes, Astrocytes). Based on its differentiation technologies, the company is advancing two therapeutic programs focused on diabetes mellitus and ALS, where stem cells are differentiated into beta cells (for the diabetes program) and astrocytes (for the ALS program) with the goal of implanting them into patients, and affecting diseases progression. Also collaborating for optimizing drug development through pluripotent stem cell-derived cells.
- Oct 2021Post IPO$5M
- Oct 2018Post IPO$5.2M
- Mar 2018Grant (prize money)$319.4K
- Dec 2016Post IPO$7M
#12
Deadpooled · Ness Ziona, Center District · founded 2008 · 6 employees$23Mraised▾
Regenera Pharma is an Israeli, clinical stage biopharma developing botanically-derived small molecule therapeutics for optic nerve disorders. Its lead candidate RPh201, an extract of Mastic Gum, is a G protein-coupled receptor (GPCR) antagonist which is currently in phase 2 study for Traumatic Neuropathy or Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION). It is also planning to extend this product applications for the other neurodegenerative indications.
- Jan 2018Series A$20M
- May 2015Series A$3M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in Israel
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 267 Israel-affiliated papers.
- Ministry of Agriculture118
- Hebrew University of Jerusalem29
- Agricultural Research Organization25
- Tel Aviv University21
- Ben-Gurion University of the Negev19
- Mitochondrion1→5
- Gene1→18
- Plant disease resistance1→7
- Resistance (ecology)2→6
- Agriculture3→6
Where biotechnology is researched across Israel
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.